Printer Friendly

PHARMOS CORPORATION PRESENTS FIRST STUDIES ON NOVEL ANTIGLAUCOMA NEUROPROTECTIVE AGENT

 SARASOTA, Fla., May 3 /PRNewswire/ -- Pharmos is presenting additional research data on its novel neuroprotectant, HU-211, which Pharmos is developing as a new pharmacological approach to glaucoma. HU-211 has shown activity in both neuroprotection and the lowering of intracular pressure (IOP). This combination of attributes suggests that this group of molecules can provide a potentially unique approach, lowering IOP while also protecting the optic nerve. Also being presented at ARVO are the results of human clinical trials using Pharmos' new SubMicron Emulsion formulation of an established glaucoma therapy and data showing the improved performance of a number of ocular drugs, when formulated with SME technology.
 In the study being presented by Dr. Mark Beilin and Dr. Ron Neumann of Pharmos, researchers cut intraocular pressure in half using SubMicron Emulsion (SME)-formulated HU-211. 50 ul of the compound were administered with follow-up readings taken, 1, 3, 5 and 7 hours and later whenever pertinent. The study concluded a 50 percent reduction in intraocular pressure was observed following one drop of 0.25 percent HU-211 in SME, indicating a significant reduction in aqueous humer flow.
 Pharmos Corporation is engaged in the development of novel pharmaceuticals based on innovative drug delivery technologies targeting diseases of the eye, principally glaucoma and ocular inflammation, and the brain, principally stroke and head trauma.
 -0- 5/3/93
 /CONTACT: Stephen R. Streber, president & COO of Pharmos Corporation, 212-838-0087; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Pharmos Corporation; or Donald C. Weinberger of Strategic Growth International, 212-826-9622/
 (PARS)


CO: Pharmos Corporation ST: New York IN: MTC SU:

TS-WB -- NY072 -- 3855 05/03/93 13:47 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:273
Previous Article:PHARMOS CORPORATION CONTINUING PROGRESS IN OPHTHALMIC RESEARCH
Next Article:UNIQUE APPROACH HELPS COMPANIES; FIRM COACHES TOP EXECUTIVES IN THE ART OF CHANGE
Topics:


Related Articles
PHARMOS CORPORATION CONTINUING PROGRESS IN OPHTHALMIC RESEARCH
PHARMOS CORPORATION ADDRESSES KEY COMPLIANCE ISSUES WITH SME TECHNOLOGY
PHARMOS CORPORATION'S NOVEL NEUROPROTECTIVE COMPOUND, HU-211, RECEIVES ADDITIONAL PATENT FOR STROKE AND HEAD TRAUMA
PHARMOS' TREATMENT SHOWS EFFICACY IN GIANT PAPILLARY CONJUNCTIVITIS; PHARMOS REPORTS DATA FROM CLINICAL STUDIES
PHARMOS RESEARCHERS PRESENT DATA ON HU-211 AS A NEUROPROTECTANT IN STROKE AND HEAD TRAUMA
PHARMOS RESEARCHERS PRESENT DATA ON THE THERAPEUTIC VALUE OF HU-211, A NEUROPROTECTANT IN HEAD TRAUMA AND STROKE
PHARMOS DRUG DELIVERY SYSTEM OVERCOMES BIOLOGICAL BARRIERS
PHARMOS SUBMITTED LOTEMAX CLINICAL PACKAGE TO FDA ADDRESSING $500 MILLION MARKET
PHARMOS PRESENTS LOTEMAX CLINICAL RESULTS AT ARVO CONVENTION
Pharmos Initiates Phase II Study to Evaluate Dexanabinol in Traumatic Head Injury Patients

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters